Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-positive breast cancer, drawn from the whole corpus: 175 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
2 medicines on record are linked to one of the types below rather than to HER2-positive breast cancer itself. Grouped by the type that holds them; each list opens that type's own page.
Sequencing after T-DXd: no randomised data on which HER2 ADC or TKI works after TOP1-payload failure.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Interstitial lung disease with T-DXd in curative settings, where patients would otherwise be cured.
Over-treatment: which patients need pertuzumab, a full year of antibodies, or any chemotherapy at all (PHERGain-2, response-adapted trials).
Brain metastasis prevention and whether systemic-first strategies preserve cognition.
Background: HER2-positive brain metastases, The blood-brain barrier & brain metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
HR+/HER2+ ('triple-positive') disease: optimal integration of endocrine therapy, CDK4/6 inhibitors, and HER2 blockade.
Cardiotoxicity surveillance burden versus event rates in low-risk patients.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Global access: biosimilars have widened trastuzumab access but pertuzumab, T-DM1, and T-DXd remain unavailable in much of the world.
Background: Biosimilar. Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
HER2 heterogeneity and HER2 conversion at relapse require re-biopsy strategies or HER2 PET.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 90 changes by month →FDA approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
When this page itself was last checked or edited.
With trastuzumab and pertuzumab, maintenance after induction for unresectable or metastatic HER2-positive breast cancer (FDA, 7 October 2026)
A milestone in how this cancer is treated.
Phase 3 vs T-DM1 in residual disease registered (NCT06830889)
Unresectable or metastatic HER2-positive breast cancer after one or more anti-HER2 therapies